A new method can improve treatment for patients with chronic myeloid leukemia by predicting which medication will be most ...

The pharma company now has two positive proof-of-concept trials under its belt, including its weight-loss pill.

Compelling molecular responses starting at lowest dose level in heavily pre-treated patients with high baseline BCR-ABL ...

In this randomized controlled trial, among adults diagnosed with chronic myeloid leukemia (CML), asciminib demonstrated a ...

TERN-701 showed promising early results, with significant molecular responses and a strong safety profile in heavily ...

Kolibaba, KS, Druker BJ. Current Status of Treatment for Chronic Myelogenous Leukemia. MedGenMed 2(2), 2000 [formerly published in Medscape Hematology-Oncology eJournal 3(2), 2000]. Available at ...

US regulators’ use of a speedy clearance pathway for a new frontline indication for asciminib for chronic myeloid leukemia ...

A new method can improve treatment for patients with chronic myeloid leukemia by predicting which medication will be most ...

Terns Pharmaceuticals Inc.’s stock jumped 7.5% premarket Tuesday, after the company announced positive data from an ...

Chronic Myeloid Leukemia (CML) is a cancer that starts in the blood-forming cells of the bone marrow and can spread into the blood. Affecting over 1.2 to 1.5 million people worldwide , CML presents ...

High cumulative doses of epipodophyllotoxins were associated with the highest risk for survivors of childhood cancer of ...